Skip to main content

Pay Bill Portals

Our Tests
Our Services
- - Oncology
    - - SERVICES
        
        NateraCore Services
        
        Pharma Partnership
        
        Real-World Data
        
        EMR Integration
    - - FOR PATIENTS
        
        Schedule a Genetic Information Session
        
        Schedule Session with Patient Coordinator
        
        Pricing and Billing Information
        
        Contact Us
    - - FOR CLINICIANS
        
        Schedule Session With Client Services
        
        Oncology Portal
        
        Order a Test Kit
        
        Contact Us
  - Organ Health
    - - SERVICES
        
        NateraCore Services
        
        ProReach
        
        EMR Integration
        
        Pharma Services
    - - FOR PATIENTS
        
        Schedule a Genetic Information Session
        
        Order a Renasight Kit
        
        Contact Us
        
        Pricing and Billing Information
    - - FOR CLINCIANS
        
        Organ Health Portal
        
        Order a Renasight Kit
        
        Contact Us
  - Women’s Health
    - - SERVICES
        
        NateraCore Services
        
        Constellation
        
        EMR Integration
    - - FOR PATIENTS
        
        Schedule a Genetic Information Session
        
        Pricing and Billing Information
        
        Women’s Health Portal
        
        Contact Us
    - - FOR CLINICIANS
        
        Order Tests and Track Status on NateraConnect
        
        View Patient Results on NateraConnect
        
        Contact Us
  - Rare Disease
    - - SERVICES
        
        EMR Integration
    - - FOR PATIENTS
        
        Schedule a Zenith™ Genetic Information Session
        
        Billing Information
    - - FOR CLINICIANS
        
        Rare Disease Portal
        
        Order a Test Kit
        
        Contact Us
Patient Resources
- - Oncology
    - - LEARN
        
        Signatera
        
        Altera
        
        Empower
        
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule a Genetic Information Session
        
        Schedule Blood Draw (Existing Patients)
        
        Schedule Session with Patient Coordinator
        
        Pricing and Billing Information
    - - CONNECT
        
        Contact Us
  - Organ Health
    - - LEARN
        
        Prospera
        
        Renasight
        
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule Blood Draw (Existing Patients)
        
        Schedule a Genetic Information Session
        
        Pricing and Billing Information
    - - CONNECT
        
        Contact Us
  - Women’s Health
    - - LEARN
        
        Horizon
        
        Panorama
        
        Empower
        
        Vistara
        
        Anora
        
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule a Genetic Information Session
        
        Schedule Blood Draw (Existing Patients – USA)
        
        Schedule Blood Draw (Existing Patients – Canada)
        
        Pricing and Billing Information
        
        Women’s Health Portal
    - - CONNECT
        
        Contact Us
  - Rare Disease
    - - EXISTING PATIENTS
        
        Schedule a Zenith™ Genetic Information Session
        
        Billing Information
Clinical Resources
- - Oncology
    - - CLINICAL RESOURCES
        
        Signatera
        
        Signatera Publications
        
        Altera
        
        Empower
        
        View All Clinician Resources
    - - RESEARCH STUDIES
        
        Signatera Research Pipeline
        
        Natera Sponsored Trials
    - - CONNECT
        
        Oncology Portal
        
        Contact Us
  - Organ Health
    - - CLINICAL RESOURCES
        
        Organ Health Publications
        
        Prospera
        
        Renasight
        
        View All Clinician Resources
    - - RESEARCH STUDIES
        
        ProActive Study
        
        PEDAL Study
        
        Trifecta Study
        
        MOTR Study
    - - CONNECT
        
        Organ Health Portal
        
        Contact Us
  - Women’s Health
    - - CLINICAL RESOURCES
        
        Women’s Health Publications
        
        Horizon
        
        Panorama
        
        Empower
        
        Vistara
        
        Anora
        
        Natera Academy Provider Education Hub
        
        View All Clinician Resources
    - - RESEARCH STUDIES
    - - CONNECT
        
        Contact Us
  - Rare Disease
    - - CLINICAL RESOURCES
        
        Zenith™ Clinician Information
    - - CONNECT
        
        Rare Disease Portal
        
        Contact Us
Company
Search for:
Pay Bill

Portals
Search for:

Natera, Inc.

- Altera
- Anora
- Empower
- Horizon
- Panorama
- Prospera
- Renasight
- Signatera
- Spectrum
- Vistara
- Blog
- Videos
- Brochure
- Whitepaper
- Manual
- Poster
- Report
- Study
- Webinars
- Natera Academy

Recent Searches

Home
Oncology
Circulating Tumor DNA in High‐Risk Stage II/III Cutaneous Melanoma: A Feasibility Study

Circulating Tumor DNA in High‐Risk Stage II/III Cutaneous Melanoma: A Feasibility Study

Published Date March 10, 2026

Rhodin KE, O’Connor MH, Therien A, et al. Ann. Surg. Oncol. 2025

Previous Resource

ctDNA Dynamics Identifies Pseudoprogression in a Metastatic Melanoma Patient Treated With Nivolumab/Relatlimab

Steimle AK, Cho SY, Menon N, et al. Journal of Immunotherapy 2025
Next Article

Understanding Your Risk: The Role of Hereditary Cancer Testing in Prevention

Related Content

about 2 hours ago
Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in

Ma VT., Zhou AY., Forati A., et al. JCO PO 2026

Read More
about 2 hours ago
Longitudinal ctDNA monitoring for post-surgical disease surveillance in patients with stage I-IIIB melanoma

Ansstas G., Khaddour K., Sudhaman S., et al. CCR. 2026

Read More
about 2 hours ago
Sensitivity of Circulating Tumor DNA for Detection of Minimal Residual Disease Recurrence or Relapse in Patients With Melanoma

Steimle AK., Harris MS, Forati A, et al. JCO OA. 2026

Read More
about 2 hours ago
Circulating Tumor DNA Predicts Response After Definitive Radiation Therapy for Merkel Cell Carcinoma

Murchison, K., Camargo, A., Margalit, D., et al. Adv. Radiat. Oncol. 2026

Read More
about 2 hours ago
Genomic profiling guided therapy for synchronous SCC and CLL of the parotid gland: a rare case report

Dahiya, R., Weiss, N., Wilson, P., et al. J Surg Case Rep. 2025

Read More
about 2 hours ago
Personalized Circulating tumor DNA assay to assess long-term clinical benefit in patients with advanced melanoma

Martinez-Villa C, Teixido C, Martin R, et al. Cancers 2025

Read More
about 2 hours ago
Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient management

Akaike T, Thakuria M, Silk AW, et al. J Am Acad Dermatol. 2025

Read More
about 2 hours ago
ctDNA Dynamics Identifies Pseudoprogression in a Metastatic Melanoma Patient Treated With Nivolumab/Relatlimab

Steimle AK, Cho SY, Menon N, et al. Journal of Immunotherapy 2025

Read More
Understanding Your Risk: The Role of Hereditary Cancer Testing in Prevention

Read Article
Expanded eligibility for Natera’s Financial Assistance Program

Read Article
11 days ago
Dynamics of Tumor-informed Circulating Tumor DNA and Association with Clinical Responses to Enfortumab and Pembrolizumab in Patients with Lo

. Vlachou, B.A. Johnson 3rd, M. Kates et al, Eur Urol Open Sci (2025)

Read More
11 days ago
Dr. Ari Rosenberg SINERGY Data Summary

Dr. Ari Rosenberg from the University of Chicago gives a summary on the SINERGY Trial data that he presented during an oral plenary session at MHNCS.

Watch Video
22 days ago
Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort Study

Ando K, Hamabe A, Nakamura Y, et al. Ann Surg. 2026

Read More
What ASCO GI 2026 Means for Patients: How MRD Research Is Shaping GI Cancer Care

Read Article
27 days ago
Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy

Chakrabarti S, et al. Cancers. 2026

Read More
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer A Nonrandomized Clinic

Han, H.S. et al; JAMA Oncology 2025

Read More
Adjuvant endocrine therapy with cyclindependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/ HER2– breast canc

Spring L. M. et al; npj Breast Cancer 2025

Read More
Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasi

Foldi J; JCO Precision Oncology 2025

Read More
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpas

Mittendorf E. A. et al; Nature Medicine 2025

Read More
Circulating Tumor DNA (ctDNA) is Reliably Detected in Patients with Metastatic Malignant Phyllodes Tumors, a Feasibility Study

Reason E. H. et al; Ann Surg Oncol 2025

Read More

Return to Resource Library

© Natera, Inc.

Our Tests
Our Services
Patient Resources
Clinical Resources
- Resource Library
- Provider Portals
Company
Contact

Natera Licenses
IT Security Compliance
Natera Notice of Data Collection for California Residents
HIPAA Notice of Privacy Practices
Privacy Policy
Terms of Use
Sitemap

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved.